凯莱英医药集团（天津）股份有限公司（06821）10月23日公告称，公司第五届董事会第十六次会议已于2026年10月22日以现场结合通讯方式召开，9名董事全部出席，会议程序符合相关法律法规及《公司章程》规定。会议审议并全票通过两项议案：
1. 审议通过《2026年第三季度报告》。公司表示，该报告真实反映了报告期内的经营情况，表决结果为同意9票、反对0票、弃权0票。报告已获董事会审计委员会审议，并于同日发布在《中国证券报》《证券时报》及巨潮资讯网。
2. 审议通过《关于申请注册香港交易所联讯通并授权相关人士办理相关事宜的议案》。董事会授权执行董事张达作为公司在香港交易所「联讯通」平台的发行人管理员，负责账户注册、档案设立、用户权限管理及相关文件签署等事宜。该议案同样以9票同意、0票反对、0票弃权获得通过。
公告同时披露，董事会决议文件等备查文件已按规定存档。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.